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Abstract. Infectious bovine keratoconjunctivitis (IBK), also known as pinkeye, is the most costly eye disease of cattle. The
principal etiologic agent of IBK is the Gram-negative bacterium Moraxella bovis. However, there have been reports of IBK
outbreaks associated with Moraxella bovoculi. A retrospective study of IBK diagnostic cases submitted from July 1, 2010
through October 31, 2013 was conducted. Included in the study were 1,042 Moraxella isolates from 1,538 swabs of lacrimal
secretions collected from 282 herds from 30 U.S. states. Moraxella isolates were identified to the species level and were
composed of M. bovoculi (701 isolates), M. bovis (295 isolates), Moraxella ovis (5 isolates), and other Moraxella spp. (41).
Minimum inhibitory concentrations required for 90% growth inhibition (MIC90) was calculated for representative isolates. The
MIC90 values for both M. bovis and M. bovoculi were as follows: ampicillin and ceftiofur: ≤0.25 µg/ml; clindamycin: 2 µg/ml;
danofloxacin and enrofloxacin: ≤0.12 µg/ml; florfenicol: 0.5 µg/ml; gentamicin: 1 µg/ml; neomycin: 4 µg/ml; tulathromycin:
2 µg/ml; and tylosin: 8 µg/ml. The MIC90 values for M. bovoculi included the following: chlortetracycline: ≤0.5 µg/ml;
oxytetracycline: 4 µg/ml; penicillin: 0.25 µg/ml; spectinomycin: 32 µg/ml; sulfadimethoxine: >256 µg/ml; tiamulin: 1 µg/
ml; and trimethoprim–sulfamethoxazole: 4 µg/ml. For M. bovis, MIC90 values included the following: chlortetracycline and
oxytetracycline: 1 µg/ml; penicillin: ≤0.12 µg/ml; spectinomycin: 16 µg/ml; sulfadimethoxine: ≤256 µg/ml; tiamulin: ≤0.5 µg/
ml; and trimethoprim–sulfamethoxazole: ≤2 µg/ml. The current work describes the frequency of isolation and differences in
antimicrobial sensitivity observed among Moraxella isolates from case submissions.
Key words: Infectious bovine keratoconjunctivitis; Moraxella bovis; Moraxella bovoculi.

Introduction
Infectious bovine keratoconjunctivitis (IBK), also known as
pinkeye, is a common and costly eye disease of domestic
cattle.28,29 Cattle with IBK demonstrate a variety of clinical
signs, including increased tear production, sensitivity to
light, and ultimately corneal swelling that progresses into
corneal ulceration and possible blindness.2 Very little is
understood about the impacts of IBK on animal welfare30;
however, pain assessment studies demonstrate that it is a
painful and irritating condition.13 Economic losses in the
beef industry can be tremendous, where a 15.9-kg loss in
weaning weight per head has been estimated.20 Midwestern
U.S. beef herds report that IBK is endemic in nearly 50% of
herds with a prevalence of 8.75 out of 100 cattle affected.29
Adequate and timely treatment of acute IBK with antimicrobial therapy is frequently challenging due to many animals
being remotely pastured or grazed during peak occurrence in
the summer months.26
The principal etiologic agent for IBK is the Gram-negative bacterium Moraxella bovis.19 One of the major virulence
factors of M. bovis is a secreted cytotoxin that has been

shown to reproduce IBK lesions in calves.10 This toxin is a
repeats-in toxin (RTX), which forms pores in the membranes
of target host cells causing lysis and cell death.11 Moraxella
bovoculi, a newly described species in the genus Moraxella,
has been isolated and characterized in association with IBK
in the absence of M. bovis.9 Additional evidence for the role
of M. bovoculi in the causation of IBK includes secretion of
a RTX class cytotoxin similar to that of M. bovis.6 However,
studies evaluating vaccine efficacy show a decrease in incidence of IBK neither when M. bovoculi was included in an
autogenous vaccine formulation15 nor when subunit M.
bovoculi cytotoxin was used as a vaccine in calves.8 Direct
inoculation of M. bovoculi into scarified calf corneas does
not cause IBK lesions, making the direct role of M. bovoculi
in IBK pathogenesis uncertain.18 The data indicates that
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although M. bovoculi is isolated in cases of IBK, there is no
direct evidence supporting a causal role, and temporal associations of M. bovoculi and correlation of eye colonization
with disease have been difficult to determine.21 In order to
further characterize the microbial populations present in
bovine eyes during outbreaks of IBK, a retrospective study
was undertaken to assess the composition of Moraxella spp.
in a large number of diagnostic submissions, as well as to
assess the antimicrobial susceptibility patterns to selected
antimicrobial agents of representative isolates from diagnostic submissions.

Materials and methods
Samples included in the current study were comprised of
diagnostic laboratory submissions received from July 1,
2010 to October 31, 2013 that had been submitted as diagnostic cases to the Nebraska Veterinary Diagnostic Center
(Lincoln, Nebraska). Data was extracted from a laboratory
information management software system (LIMS) that
includes all diagnostic submissions over the time period. A
subset of data was extracted into spreadsheet software
including case submissions of swabs of lacrimal secretions
collected from bovine eyes during cases of IBK in beef or
dairy herds. For some diagnostic submissions, a specific
state or geographic region where the herd was located in
which the sample was taken was not included on the submission information. Herd data was based on unique accession
numbers assigned to each case. Individual data was determined based on a unique individual identification number
present on a case submission form. Isolation of Moraxella
spp. on eye swabs was conducted by trained technicians following standard operating procedures in an American Association of Veterinary Laboratory Diagnosticians (AAVLD)
fully accredited laboratory. Data entry into LIMS was performed by the technician, and results were reviewed by a
laboratory manager and a case coordinator for accuracy. The
protocol used by all trained technicians in the laboratory at
the time period, to determine if viable Moraxella spp. were
present in the samples, was as follows: Swabs were streaked
onto tryptic soy agar containing 5% sheep’s blood and incubated for 18–24 hr at 37°C with 5% CO2 supplementation.
Bacterial colonies with morphology consistent with members of the genus Moraxella were further screened for oxidase production. Colonies positive for oxidase production
were then subjected to Gram staining and were subcultured
for purity. All subcultured organisms that were characterized
as Gram-negative rods or coccobacilli by Gram stain were
subjected to molecular speciation. Isolates were subsequently identified as M. bovis, M. bovoculi, or Moraxella
ovis based on a polymerase chain reaction (PCR) assay and a
subsequent restriction fragment length polymorphism analysis that targets the 16S-23S intergenic spacer region in combination with phenotypic tests as needed.4 Some isolates
could not be definitively identified based on PCR data and
phenotypic data, and were categorized as Moraxella sp.

For PCR testing, genomic DNA was extracted from 24-hr
subculture growth by picking out several well-isolated colonies with a sterile stick and then resuspending the colonies
into 100 µl of nuclease-free water to a 1–2 McFarland standard turbidity. Cell suspensions were boiled at 100°C for 10
min to lyse bacterial cells. Cell debris was clarified by centrifugation at 15,700 × g for 2 min. Extracted nucleic acid
was subjected to PCR using primersa ISRdown
(5′-GTGAAGTCGTAACAAGGTAGCCGT-3′) and ISRup
(5′-ACCGACGCTTATCGCAGGCTATCA-3′).4 The PCR
master mixb consisted of 50 µl, which contained nucleasefree H2O (32.1 µl), 5.0 μl of 10× reaction buffer, 4.0 μl of
MgCl2 (50 mM), 0.5 µl of deoxyribonucleotide triphosphates
(100 mM), 2.5 µl of ISRup (10 μM), 2.5 µl of ISRdown (10
μM), 0.4 µl of Taq polymerase (5 U/µl), and 3.0 µl of template DNA. The PCR reactions were subjected to thermocycling under the following conditions; 95°C for 60 sec, then
40 cycles of 95°C for 30 sec, 55°C for 30 sec, and 72°C for
30 sec and a final extension of 72°C for 7 min. Amplicons
were then digested with restriction endonuclease AfaIc and
subjected to a 60-min digestion at 37°C. Digested DNA (15
µl) was resolved using capillary gel electrophoresis.d Interpretation of molecular weight fragments corresponding to
M. bovoculi, M. ovis, and M. bovis was 450- and 150-bp,
600-bp, and 650-bp fragments, respectively.
As part of the diagnostic workup of each case submission,
representative isolates were selected on a herd level based on
similar colony growth characteristics and PCR speciation.
The representative isolates were then subjected to antimicrobial sensitivity testing. Because of the small number of M.
ovis isolates and possible diversity within the Moraxella sp.
isolated, these organisms were excluded from the antimicrobial susceptibility analysis. To conduct in vitro antimicrobial
sensitivity, a broth microdilution system was used following
Clinical Laboratory Standards Institute (CLSI) guidelines.12
Several colonies of pure culture were suspended into 10 ml
of sterile demineralized water to a 0.5 McFarland standard
and vortexed to ensure uniform resuspension. Inoculation
density was confirmed using a calibrated nephelometer. A
10-µl aliquot of the resuspended organism was then inoculated into 11 ml of sterile inoculation media and vortexed to
ensure uniform resuspension. A 100-µl aliquot of culture per
well was then inoculated into bovine and/or porcine antimicrobial susceptibility panelse with an autoinoculator. Samples were incubated at 35°C for 18 hr without carbon dioxide
supplementation and were read automatically with the minimal inhibitory concentration (MIC) determined using an
automated system.f The auto-read values were confirmed
manually by observation as necessary. Quality control organisms used for assays include Staphylococcus aureus (ATCC
29213), Enterococcus faecalis (ATCC 29212), and Escherichia coli (ATCC 25922). No specific CLSI-approved interpretative criteria exist for Moraxella spp. in cattle, therefore
interpretive criteria established for bovine respiratory disease or other Gram-negative veterinary isolates as available
were used, with organisms classified as susceptible (S),
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Table 1. Selected antimicrobial drugs utilized in broth microdilution testing for minimum inhibitory concentrations, the range
of concentrations evaluated for each antimicrobial, and interpretive criteria (susceptible, intermediate, or resistant) applied to each
antimicrobial tested.
Concentration(s) tested
(µg/ml)

Antimicrobial
Ampicillin
Ceftiofur
Chlortetracycline
Clindamycin
Danofloxacin
Enrofloxacin
Florfenicol
Gentamicin
Neomycin
Oxytetracycline
Penicillin
Spectinomycin
Sulfadimethoxine
Tiamulin
Tilmicosin
Trimethoprim–sulfamethoxazole
Tulathromycin
Tylosin

0.25–16
0.25–8
0.5–8
0.25–16
0.12–1
0.12–2
0.25–8
1–16
4–32
0.5–8
0.12–8
8–64
256
0.5–32
4–64
2/38†
1–64
0.5–32

Susceptible
≤0.5
≤2
≤2
≤0.5
≤0.25
≤0.25
≤2
≤2
*
≤2
≤0.25
≤32
≤256
≤16
≤8
<2/38
≤16
*

Intermediate

Resistant

1
4
4
1–2
*
0.5–1
4
4
*
4
0.5
64

≥2
≥8
≥8
≥4
*
≥2
≥8
≥8
*
≥8
≥1
≥128
>256
≥32
≥32
≥2/38
≥64
*

16
32
*

* No interpretive criteria available.
† A single concentration of 2 µg/ml trimethoprim in combination with 38 µg/ml sulfamethoxazole (2/38) was tested.

intermediate (I), or resistant (R; Table 1).12 Breakpoints were
not available for neomycin and tylosin. For trimethoprim–
sulfamethoxazole and sulfadimethoxine only a single drug
concentration was tested. Percent susceptibility (% susceptible) was determined by dividing the number of organisms
with MIC values that fell into a susceptible MIC breakpoint
(numerator) by the total tested (denominator) and multiplying by 100. The MIC50 and MIC90 values were defined as the
concentration of antibiotic that was capable of inhibiting
growth of 50% and 90% of total tested isolates.

Results
A total of 1,538 samples were included in the data set. Of
these, 600 had no growth of Moraxella spp. or were too contaminated with overgrowth to determine if there were Moraxella organisms present in the specimen. Out of this total, 938
swabs had growth of 1 or more Moraxella spp., and the total
number of isolates subjected to identification was 1,042 as
some had multiple species present. Submitted samples
included case submissions from cases of IBK in 30 states.
Submissions from 29 out of 30 states had at least 1 Moraxella sp. isolated. The number of submitted samples on a
state-by-state basis that contained at least 1 Moraxella spp.
isolated as well as the number of herds from which these
samples originated, is indicated (Fig. 1). For 261 herds, geographic information was sufficient to determine the state of
origin for the submission. On individual animal level 938

submissions were identified. The frequency of isolation of
Moraxella in individuals included: M. bovis: 193; M. bovoculi: 600; M. ovis: 4; Moraxella sp.: 37; M. bovis and M.
bovoculi: 99; M. bovoculi and Moraxella sp.: 1; M. bovoculi
and M. ovis: 1; M. bovis and Moraxella sp.: 3 (Table 2).
On a herd level, 282 total herds were identified. The frequency of isolation of Moraxella spp. in herds included: M.
bovis: 18; M. bovoculi: 140; M. ovis: 2; Moraxella sp.: 7; M.
bovis and M. bovoculi: 102; M. bovoculi and Moraxella sp.:
2; M. bovoculi and M. ovis: 1; M. bovoculi and M. ovis: 1; M.
bovis and Moraxella sp.: 1; M. bovis, M. bovoculi, and M.
ovis: 1 (Table 2).
For M. bovoculi, 213 total isolates were subjected to MIC
testing against 18 antimicrobials with a range of concentrations (Table 1). MIC90 values were as follows: ampicillin,
≤0.25 µg/ml; ceftiofur, ≤0.25 µg/ml; chlortetracycline, ≤0.5
µg/ml; clindamycin, 2 µg/ml; danofloxacin and enrofloxacin, ≤0.12 µg/ml; florfenicol, 0.5 µg/ml; gentamicin, 1 µg/
ml; neomycin and oxytetracycline, 4 µg/ml; penicillin, 0.25
µg/ml; spectinomycin, 32 µg/ml; sulfadimethoxine, >256
µg/ml; tiamulin, 1 µg/ml; trimethoprim–sulfamethoxazole, 4
µg/ml; tulathromycin, 2 µg/ml; and tylosin, 8 µg/ml (Table
3). The total susceptible phenotypes observed for M. bovoculi were as follows: ampicillin, 99%; ceftiofur, 100%; chlortetracycline, 93%; clindamycin, 11%; danofloxacin, 98%;
enrofloxacin, 98%; florfenicol, 92%; gentamicin, 98%; neomycin, not determined (ND); oxytetracycline, 85%; penicillin, 96%; spectinomycin, 86%; sulfadimethoxine, 86%;
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Figure 1. Number and state-by-state distribution of case submissions that at least 1 Moraxella spp. was isolated from bovine ocular
swabs. States with at least 1 Moraxella isolate included in the analysis are shaded in dark gray. Numbers on the state indicates the total
positive case submissions received in the period, and the number in parentheses indicates the number of positive herds included in each state
over the period from July 1, 2010 to October 31, 2013.

Table 2. Profile of Moraxella spp. isolated from lacrimal
secretion swab cultures (n = 1,042).*

Species isolated
Moraxella bovis
Moraxella bovoculi
Moraxella ovis
Moraxella sp.
M. bovis and M. bovoculi
M. bovoculi and Moraxella
sp.
M. bovoculi and M. ovis
M. bovis and Moraxella
sp.
M. bovis, M. ovis, and
M. bovoculi

No. of
herds
yielding the
indicated species

No. of
individuals
yielding the
indicated species

(1)

(2)

18
140
2
7
102
2

193
600
4
37
99
1

1
2

1
3

1

0

* The number of herds with the corresponding species composition of
isolated organisms is indicated in column (1). Column (2) indicates the
number of herds with the corresponding species composition isolated from
samples.

tiamulin, 99%; tilmicosin, 92%; trimethoprim–sulfamethoxazole, 87%; tulathromycin, 92%; and tylosin, ND (Table 3).
For M. bovis, 106 total isolates were subjected to MIC
testing against 18 antimicrobials with a range of concentra-

tions (Table 1). The MIC90 values were as follows: ampicillin, ≤0.25 µg/ml; ceftiofur, ≤0.25 µg/ml; chlortetracycline, 1
µg/ml; clindamycin, 2 µg/ml; danofloxacin and enrofloxacin, ≤0.12 µg/ml; florfenicol, 0.5 µg/ml; gentamicin, 1 µg/
ml; neomycin, 4 µg/ml; oxytetracycline, 1 µg/ml; penicillin,
≤0.12 µg/ml; spectinomycin, 16 µg/ml; sulfadimethoxine,
≤256 µg/ml; tiamulin, ≤0.5 µg/ml; trimethoprim–sulfamethoxazole, ≤2 µg/ml; tulathromycin, 2 µg/ml; and tylosin,
8 µg/ml (Table 4). The total susceptible phenotypes observed
for M. bovis were as follows: ampicillin, 99%; ceftiofur,
100%; chlortetracycline, 91%; clindamycin, 21%; danofloxacin, 100%; enrofloxacin, 100%; florfenicol, 100%; gentamicin, 100%; neomycin, ND; oxytetracycline, 96%;
penicillin, 99%; spectinomycin, 100%; sulfadimethoxine,
98%; tiamulin, 99%; tilmicosin, 100%; trimethoprim–sulfamethoxazole, 98%; tulathromycin, 94%; and tylosin, ND
(Table 4).

Discussion
While previous data indicated that M. bovoculi is isolated in
association with outbreaks of IBK in the absence of M.
bovis,9,21 the current study has characterized the composition
of Moraxella isolates associated with IBK from a large number of geographically diverse case submissions in the United
States. Other authors have characterized genetic diversity
using fingerprinting among Moraxella spp. in other countries
but have not examined these on a herd or individual animal
level.27 It was observed in the current study that M. bovoculi
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Table 3. Count of Moraxella bovoculi isolates with the minimum inhibitory concentration (MIC) for each antibiotic tested.
Additionally, the MIC required to inhibit 50% and 90% (MIC50 and MIC90, respectively) of each isolate as well as the total percentage of
M. bovoculi isolates that were susceptible to each antibiotic are included (n = 213 isolates).
MIC (µg/ml)
Antimicrobial

0.12

Ampicillin
Ceftiofur
Chlortetracycline
Clindamycin
Danofloxacin
207
Enrofloxacin
207
Florfenicol
Gentamicin
Neomycin
Oxytetracycline
Penicillin
183
Spectinomycin
Sulfadimethoxine
Tiamulin
Tilmicosin
Trimethoprim–
sulfamethoxazole‡
Tulathromycin
Tylosin

0.25

0.5

1

211
207

2
4
185 11
13 119
4*

2

2
62

11
2
2
28

164

2
204

4*
2
4

21

153
4

26
2

2
2

4

8

11
4

2

11
2
200
11

4*
2
9
19*
45

16

32

64

≤256

4*
2*

2

2

142

9

2

2
11

4

6

6

17*
183

181

26
185
179
2

13
2

2
2
179 17
28§

147

4
70

>256

30

MIC50

MIC90

% susceptible

≤0.25
≤0.25
≤0.5
1
≤0.12
≤0.12
0.5
1
4
≤0.5
≤0.12
16
≤256
≤0.5
≤4
≤2

≤0.25
≤0.25
≤0.5
2
≤0.12
≤0.12
0.5
1
4
4
0.25
32
>256
1
8
4

99
100
93
11
98
98
92
98
†
85
96
92
86
99
92
87

≤1
4

2
8

92.0
†

* Endpoint of > for the MIC indicated.
† No interpretive criteria available.
‡ A single concentration of 2 µg/ml trimethoprim in combination with 38 µg/ml sulfamethoxazole (2/38) was tested.
§ Indicates MIC of >2 µg/ml as additional concentrations were not evaluated.

was the only Moraxella sp. isolated from the majority of case
submissions, when evaluated at either the herd or individual
level. These findings were unexpected, given that M. bovis
has been isolated from experimentally infected calves up to
54 days following inoculation, and thus it was thought that
M. bovis would be the predominant organism isolated in
association with IBK outbreaks.17 However, recovery of M.
bovis may be variable as pathogenesis studies have shown
that M. bovis was not observed on the conjunctival surface,
using light microscopy, 10-hr postinoculation when introduced in gnotobiotic calves.23 Other studies have shown that
M. bovoculi can be isolated from ulcers in calves experimentally inoculated with M. bovis.18 Epidemiologic investigations have also failed to establish a temporal relationship
between prior exposure and clinical IBK outbreaks with isolations of M. bovoculi.21 Analysis of the speciation data in
the current study indicates that M. bovoculi is present and
viable in most of the submissions in higher numbers than M.
bovis. Moraxella bovis, when cultured, was frequently isolated in association with M. bovoculi, and was the sole
Moraxella spp. isolated in only 18 of the 282 herd submissions. The generally accepted method for sample collection
for IBK culture is to place the swab in the ventral conjunctival sac to sample lacrimal secretions. Differences and variability in and among sampling methods and timing of

collection may result in samples that may not be representative of all organisms present in the eye conjunctiva. Additionally, the isolation of M. ovis from only 5 swabs indicates
that this species, at least in this set of samples, is likely not
significantly contributing to IBK in cattle.
Previous studies have evaluated antimicrobial resistance
patterns in M. bovis and M. bovoculi in smaller collections of
isolates individually.5,25 Additionally, a study assessing the
diversity of Moraxella spp. in IBK cases from Uruguay evaluated antimicrobial susceptibility; however, the methods utilized disk diffusion and did not measure zone sizes for
interpretation, as recommended by the CLSI, and did not use
minimum inhibitory concentration testing making comparison with this data difficult.27 The antimicrobial susceptibility
data from the present study, for M. bovoculi, is similar to a
study that examined 57 isolates from California.5 However,
there were some differences observed. Moraxella bovoculi
isolates showed a reduced level of in vitro susceptibility to
the tetracycline class drugs, where the MIC90 for oxytetracycline was found to be 4 µg/ml instead of 1 µg/ml. This is a
four-fold increase in MIC90 value over the previously published data.6 Contrastingly, the MIC90 for M. bovis against
oxytetracycline was previously reported as 32 µg/ml,25
whereas a much lower MIC90 of 1 µg/ml was found in the
current study. The MIC90 of tulathromycin for both M. bovis
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Table 4. Count of Moraxella bovis isolates with the minimum inhibitory concentration (MIC) for each antibiotic tested. Additionally,
the MIC required to inhibit 50% and 90% (MIC50 and MIC90, respectively) of each isolate as well as the total percentage of M. bovis
isolates that were susceptible to each antibiotic are included (n = 106 isolates).
MIC (µg/ml)
Antimicrobial
Ampicillin
Ceftiofur
Chlortetracycline
Clindamycin
Danofloxacin
Enrofloxacin
Florfenicol
Gentamicin
Neomycin
Oxytetracycline
Penicillin
Spectinomycin
Sulfadimethoxine
Tiamulin
Tilmicosin
Trimethoprim–
sulfamethoxazole‡
Tulathromycin
Tylosin

0.12

0.25
105
104

100
103

99

0.5

1

2

4

8

16

32

64

≤256

>256

1
2
93
22

2
67

6
3
72

33

1
106
8

6

94
1

1
15

10*
2

105
1

1
3
98

8
104

98

6

104
8

1

11

104

1
95
2§

1
21

45

29

1
3

2

6

MIC50

MIC90

%
susceptible

≤0.25
≤0.25
≤0.5
1
≤0.12
≤0.12
0.5
1
4
≤0.5
≤0.12
16
≤256
≤0.5
≤4
≤2

≤0.25
≤0.25
1
2
≤0.12
≤0.12
0.5
1
4
1
≤0.12
16
≤256
≤0.5
8
≤2

99
100
91
21
100
100
100
100
†
96
99
100
98
99
100
98

≤1
4

2
8

94
†

* Endpoint of > for the MIC indicated.
† No interpretive criteria available.
‡ A single concentration of 2 µg/ml trimethoprim in combination with 38 µg/ml sulfamethoxazole (2/38) was tested.
§ Indicates MIC of >2 µg/ml as additional concentrations were not evaluated.

and M. bovoculi fell within the susceptible range of 2 µg/ml.
However, there were 16 isolates of M. bovoculi with MIC
values of 8 or greater for tulathromycin, with 6 of these isolates with MIC values of 64 µg/ml or greater. This is important to note, as oxytetracycline and tulathromycin are 2
antimicrobials with label claims for treatment of IBK associated with M. bovis.
Other antimicrobial drugs have been reported to be effective at treating IBK, including penicillin,1,3 cloxacillin
benzathine,17 ceftiofur,14 clindamycin,24 florfenicol,7 and
tilmicosin.31 A systematic review of randomized clinical trials
examining IBK pharmacological studies indicated that direct
comparisons between therapies were lacking, making drug
comparisons challenging.22 Evaluation of antimicrobial efficacy for therapy cannot be determined based on susceptibility
patterns; however, in vitro testing of M. bovis and M. bovoculi
indicate susceptibility to most of the antimicrobials, with
MIC90 values falling into the susceptible category. The lowest
percentage of susceptibility was seen with clindamycin; however, a significant number of organisms fell in the intermediate interpretive category for clindamycin (70 and 17 for M.
bovoculi and M. bovis, respectively) making the number of
isolates in the resistant category quite low, with a MIC90 of 2
µg/ml for both Moraxella species. While previous reports of
antimicrobial susceptibility testing have shown elevated

resistance to penicillin for M. bovoculi (12.3%),5 data in the
present study showed only a 4% level of resistance. The antimicrobial resistance patterns appear similar between geographically distinct M. bovis and M. bovoculi isolates,
indicating that infections with either or both organisms show
similar susceptibility patterns as previously noted.5 However,
it should be noted that there are some small differences, as the
MIC90 of M. bovoculi for oxytetracycline was higher than for
M. bovis (4 µg/ml compared with 1 µg/ml).
Differences in these susceptibility patterns may be indicative of regional preference for antimicrobial usage to treat
IBK, and the emergence of these patterns may be based on
selective pressure. Other factors that may influence this difference include transmission of resistance genotypes on a
regional level, as all of the previously tested M. bovoculi isolates were from California and the current study was biased
toward Midwestern U.S. states but included other states.
Antimicrobial treatment prior to sampling was unable to be
determined as this was not routinely included in the case histories on the submissions forms. However, prior treatment
with antimicrobials may affect in vitro susceptibility data,
and knowledge of a treatment history may enable more analysis of these patterns.
In conclusion, M. bovoculi is the most prevalent and frequent of the Moraxella sp. isolated in IBK cases in cattle

Retrospective study of Moraxella spp. associated with IBK
submitted to the Nebraska Veterinary Diagnostic Center on
both individual and herd levels. Over 600 of the 1,042 isolates tested were M. bovoculi. In nearly half (102/282) of the
herds tested, both M. bovoculi and M. bovis were isolated
from 1 or more animals in those herds. The frequency of coisolations may indicate that M. bovoculi may be serving as an
opportunistic agent or colonizing eyes in conjunction with
M. bovis, which has been shown experimentally to induce
characteristic ulcers in gnotobiotic calves.23 Further work
should be conducted to elucidate the temporal factors and
role of coinfections with M. bovoculi and M. bovis in IBK
pathogenesis that would enable further interpretation of this
data.
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